Artificial intelligence has demonstrated the ability to differentiate bottles of ophthalmic medications and could feasibly function on a smartphone platform, according to a study published in Ophthalmology Glaucoma. Researchers pretrained seven convolutional neural network (CNN) models to classify five common ophthalmic medications using a set of 2,250 images captured by mobile phones. The two top-performing networks were included in separate iOS …
Topcon Healthcare, RetInSight to Partner on AI Technology
Topcon Healthcare reported Aug. 3 that it would integrate the retina AI technology of RetInSight GmbH, of Austria, into its OCT devices and Harmony cloud-based data management technology under a new partnership. Financial details were not disclosed. The Oakland, New Jersey, company, part of Tokyo-based Topcon Corporation, said the move was designed to lead to improved clinical decision making and …
Eyecelerator Innovation Forum Draws More than 500 Attendees
Industry, clinicians, and entrepreneurs who walked into Eyecelerator’s first in-person meeting were elated to be face to face, with jokes flying about Zoom dress codes and the lack of barking dogs during conversations. The business forum took place July 22 in conjunction with the 2021 meeting of the American Society of Cataract and Refractive Surgery at the Mandalay Bay Convention …
Regeneron Announces Topline Phase 2 Data of High-Dose Aflibercept in Wet AMD
Regeneron Pharmaceuticals announced that an ongoing phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). In this small trial involving 106 patients, a higher proportion of patients in the aflibercept …
Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth
Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical device market to grow from nearly $800 million in 2021 to $1.7 billion in 2026, at …
Eyeque Announces Series C Closing With More Than $57 Million in Capital Raised
EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-home vision tests using optical smartphone attachments that consumers can use to self-administer a refractive …
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMD
Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing agreement with DelSiTech, a provider of biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical …
Aequus, reVision to collaborate on Stargardt disease treatment
Aequus Pharmaceuticals and reVision Therapeutics will collaborate to develop a treatment for Stargardt disease, according to a press release.In addition, the agreement grants Aequus the option to acquire the North American commercial rights to REV-0100 from reVision.
Gene therapy start-up Vedere Bio II launches to treat blindness
The company, Vedere Bio II, launched with $77 million in series A financing to develop what it calls a “mutation agnostic optogenetics technology” to restore vision. As its name suggests, Vedere Bio II is a sequel to its predecessor company, Vedere Bio, which Novartis quietly acquired last year in a deal worth up to $280 million.
AI-based eye test could help prevent severe vision loss
Researchers from Imperial College London and University College London (UCL) carried out a clinical trial using retinal imaging technology known as Detection of Apoptosis in Retinal Cells (DARC). When tested on 113 patients in the trial, the technology was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes …
